Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments — describing a full response in two patients in critical clinical condition with extensive metastases — are published in the December issue of the Journal of Nuclear Medicine (JNM), which has displayed images depicting the improvements on its cover page. {read more here}